Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 10Urinary Bladder Neoplasms 9Triple Negative Breast Neoplasms 2Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Lung Neoplasms 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1Glioblastoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

zimberelimab 1sacituzumab govitecan 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urothelial Bladder Carcinoma × sacituzumab govitecan × Genitourinary × Clear all
NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Fundación para el Progreso de la Oncología en Cantabria

Phase 2 Active not recruiting
70 enrolled
Genitourinary

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡